clofarabine has been researched along with Dysmyelopoietic Syndromes in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 24 (77.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, R; Artz, A; Godley, LA; Gurbuxani, S; Kunnavakkam, R; Larson, RA; Le Beau, MM; Liu, H; Locke, F; Odenike, O; Sipkins, D; Stock, W; Thirman, MJ; van Besien, K; White, C | 1 |
| Ali, S; Bowen, D; Burnett, AK; Hills, RK; Hunter, AE; Knapper, S; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Bryan, J; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S | 1 |
| Abkowitz, JL; Appelbaum, FR; Becker, PS; Estey, EH; Forman, SJ; Gardner, KM; Hendrie, PC; Medeiros, BC; Othus, M; Pagel, JM; Parks, C; Scott, BL; Stein, AS; Walter, RB; Wood, BL | 1 |
| DeAngelo, DJ; McDonnell, AM; Roberts, DA; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Becker, PS; Buckley, SA; Dean, C; Estey, EH; Gooley, TA; Hendrie, P; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Smith, K; Walter, RB; Wood, BL | 1 |
| Boucher, KM; Kushner, JP; Morley, K; Pierson, AS; Rudrapatna, VK; Shami, PJ; Shull, CT | 1 |
| Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR | 1 |
| Feldman, E; Ippoliti, C; James, S; Roboz, GJ; Savva, D; Thomas, CM; van Besien, K | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Daver, N; Faderl, S; Garcia-Manero, G; Hosing, C; Jabbour, E; Kadia, T; Kantarjian, HM; Khoury, JD; Maduike, R; Miller, D; Patel, K; Pemmaraju, N; Ravandi, F; Sasaki, K; Verstovsek, S | 1 |
| Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Amadori, S; Baron, F; de Witte, T; Halkes, CJ; Marie, JP; Meert, L; Meloni, G; Muus, P; Pruijt, H; Ramadan, SM; Selleslag, D; Suciu, S; Venditti, A; Vignetti, M; Willemze, R; Wittnebel, S | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S | 1 |
| Abboud, CN; Augustin, K; Cashen, A; DiPersio, JF; Luo, J; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Albertioni, F; Juliusson, G; Lotfi, K; Zhenchuk, A | 1 |
| Steensma, DP | 1 |
| Borthakur, G; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Gandhi, V; Garcia-Manero, G; Kantarjian, HM; Kwari, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Lim, SH; Mcmahan, J; Zhang, J; Zhang, Y | 1 |
| Sekeres, MA; Tiu, RV; Traina, F | 1 |
| Borthakur, G; Byrd, AL; Cortes, J; Estrov, Z; Faderl, S; Gandhi, V; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Kwari, M; Ravandi, F | 1 |
| Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
| Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Cortes, J; Craig, A; Davis, J; Du, M; Faderl, S; Freireich, EJ; Gandhi, V; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Shaked, Z; Verstovsek, S | 1 |
| Bumgardner, A; Chiao, N; Duvic, M | 1 |
| Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W | 1 |
| Faderl, S; Gandhi, V; Jeha, S; Kantarjian, HM; Wess, M | 1 |
8 review(s) available for clofarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clofarabine in the treatment of myelodysplastic syndromes.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes | 2014 |
Mechanisms of anti-cancer action and pharmacology of clofarabine.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Neoplasms | 2009 |
Novel therapies for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Aged; Alkylating Agents; Antimetabolites; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; DNA Repair; Drug Therapy, Combination; Drugs, Investigational; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; Quinolones; Sulfonamides; Therapies, Investigational | 2010 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
Clofarabine for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Humans; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2011 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases.
Topics: Adenine Nucleotides; Adolescent; Arabinonucleosides; Clofarabine; Dose-Response Relationship, Drug; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2003 |
Clofarabine: past, present, and future.
Topics: Adenine Nucleotides; Aged; Animals; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; DNA Damage; Drug Approval; Humans; Leukemia, Myeloid, Acute; Medical Oncology; Middle Aged; Models, Biological; Models, Chemical; Myelodysplastic Syndromes; Prognosis; Purines | 2007 |
20 trial(s) available for clofarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Treatment Outcome | 2013 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Young Adult | 2015 |
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Survival Rate; Time Factors | 2015 |
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2015 |
Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.
Topics: Adenine Nucleotides; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Treatment Failure | 2015 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning | 2016 |
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms; Treatment Outcome | 2017 |
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Random Allocation; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2017 |
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate | 2008 |
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Prospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine.
Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Male; Myelodysplastic Syndromes; Salvage Therapy; Treatment Failure | 2010 |
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cohort Studies; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2012 |
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome | 2012 |
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Rate; Treatment Outcome | 2003 |
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Models, Chemical; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Nucleosides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2004 |
3 other study(ies) available for clofarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clofarabine as a bridge to hematopoietic stem cell transplant.
Topics: Acute Disease; Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Combined Modality Therapy; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Survival Analysis | 2017 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |